What is the dose of Metoprolol (metoprolol) succinate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Metoprolol succinate should be initiated at a dose of 12.5-25 mg once daily and titrated up to a target dose of 200 mg once daily, as tolerated, for the management of heart failure with reduced ejection fraction (HFrEF) 1. The dosing of metoprolol succinate is crucial in achieving optimal outcomes in patients with HFrEF.

  • The initial dose of 12.5-25 mg once daily allows for gradual titration and minimizes the risk of adverse effects.
  • The target dose of 200 mg once daily is based on clinical trials that have demonstrated improved outcomes, including reduced mortality and hospitalization rates, with higher doses of metoprolol succinate 1.
  • It is essential to monitor patients regularly and adjust the dose as needed to ensure optimal beta-blockade and minimize side effects.
  • The extended-release formulation of metoprolol succinate provides steady blood levels over 24 hours, which helps maintain consistent beta-blockade throughout the day and improves adherence compared to immediate-release formulations.
  • Dose adjustments may be necessary for elderly patients or those with hepatic impairment, and blood pressure, heart rate, and symptoms should be monitored regularly to assess efficacy and adjust dosing as needed.
  • The use of lower doses of metoprolol succinate, where higher target doses could be tolerated, may not produce the same degree of clinical benefit, and therefore, titration to the target dose is recommended 1.

From the FDA Drug Label

DOSAGE & ADMINISTRATION ... In patients who tolerate the full intravenous dose (15 mg), initiate metoprolol tartrate tablets, 50 mg every 6 hours, 15 minutes after the last intravenous dose and continued for 48 hours. Thereafter, the maintenance dosage is 100 mg orally twice daily Start patients who appear not to tolerate the full intravenous on metoprolol tartrate tablets either 25 mg or 50 mg every 6 hours (depending on the degree of intolerance) 15 minutes after the last intravenous dose or as soon as their clinical condition allows. The maintenance dosage of metoprolol tartrate is 100 mg orally twice daily. However, the question asks about metoprolol succinate, not metoprolol tartrate. The FDA drug label does not answer the question.

From the Research

Metoprolol Succinate Dose

  • The optimal dose of metoprolol succinate for patients with heart failure is not explicitly stated in the provided studies 2, 3, 4.
  • However, a study comparing carvedilol, bisoprolol, and metoprolol succinate in patients with chronic heart failure found that the three beta-blockers had similar effects on mortality amongst patients with CHF 3.
  • Another study found that sacubitril/valsartan combined with metoprolol improved cardiac function, cardiac remodeling, and endothelial function in patients with coronary heart disease and heart failure, but did not specify the dose of metoprolol used 4.
  • A study on bisoprolol found that patients classified as NYHA III-IV received a 33% higher dose per kilogram of body weight than patients in NYHA I-II, but achieved 165% higher serum concentrations of bisoprolol 5.
  • The dose of metoprolol succinate may need to be individualized based on patient characteristics, such as renal function and concomitant medications, to minimize the risk of adverse reactions 5, 4.

Key Findings

  • Metoprolol succinate is effective in treating heart failure, but its optimal dose is not well established 2, 3, 4.
  • Combination therapy with sacubitril/valsartan and metoprolol may be beneficial for patients with coronary heart disease and heart failure 4.
  • Patient characteristics, such as renal function and concomitant medications, may affect the dose of metoprolol succinate required 5.

Study Limitations

  • The provided studies did not specifically investigate the optimal dose of metoprolol succinate for patients with heart failure 2, 3, 4.
  • The studies had varying patient populations, study designs, and outcome measures, making it difficult to draw firm conclusions about the optimal dose of metoprolol succinate 2, 5, 3, 6, 4.

Related Questions

What are the dosing options for Carvedilol (Coreg)?
What is the equivalent dose of carvedilol (Carvedilol) when converting from metoprolol succinate (Metoprolol) 100 mg?
What is the maximum recommended dosage of Bisoprolol (beta-blocker) for treating hypertension (high blood pressure) and heart failure?
What is the use of Coreg (Carvedilol)?
What is the difference between metoprolol (beta-blocker) succinate and metoprolol tartrate in terms of formulation and dosing?
What is the best benzodiazepine (benzo) to use during a ventricular tachycardia (VT) storm?
What is a reasonable dose of oxycodone (OxyContin), a short-acting opioid, to use as needed (prn) for complex chronic pain management in a patient with pancreatitis, undergoing Suboxone (buprenorphine and naloxone) induction for chronic pain treatment, with a preference for oxycodone?
What is the optimal treatment approach for an 81-year-old female patient with congestive heart failure (CHF), well-controlled diabetes mellitus, and well-controlled hypertension, presenting with impaired renal function, on metoprolol (Lopressor) 50 mg, furosemide (Lasix) 20 mg daily, apixaban (Eliquis) 5 mg daily, lisinopril (Zestril) 40 mg daily, and empagliflozin (Jardiance) 10 mg daily, with hyperkalemia, currently holding spironolactone (Aldactone) 25 mg?
What is the cause of supraventricular (SV) tachycardia and chills in a patient who was previously ambulating normally to the bathroom?
What is myositis ossificans?
What is the next step in evaluation for a patient with a positive T-SPOT (T-cell spot test) after contact with a confirmed tuberculosis patient, who remains asymptomatic?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.